Axil Capital
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Axil Capital.
Key people at Axil Capital.
Axil Capital is a Tokyo-based venture capital firm specializing in early to crossover-stage investments across the global biomedical and healthcare technology sectors, including biopharmaceuticals, platform technologies, medical devices, digital health, and healthcare services. Its mission centers on creating value in the life sciences ecosystem by actively supporting portfolio companies to build commercially viable enterprises with long-term impact on medicine and society, while generating returns for investors. Axil Capital’s investment philosophy emphasizes diversification across a broad range of life science technologies and fostering synergies between the Japanese biotech ecosystem and global markets, thus playing a significant role in advancing innovation in healthcare[1][2][4].
Founded in 2017 as a spin-out from Mizuho Securities, Axil Capital was established to leverage deep expertise in biomedical venture investing and to bridge Japanese and international biotech innovation. Key partners include Managing Partner Frederick Shane and Principal Dr. Akihisa Seita, among others. Since inception, the firm has evolved to focus on transformational technologies with potential for societal impact, supporting companies from seed through crossover stages. Early traction includes successful portfolio exits such as Perseus Proteomics, demonstrating their ability to nurture startups toward liquidity events[2][3][4].
Axil Capital rides the global trend of increasing investment in life sciences and healthcare innovation, driven by aging populations, rising healthcare demands, and technological advances such as digital health and precision medicine. The timing is critical as the biotech sector is experiencing rapid growth and globalization, with Japan seeking to enhance its international competitiveness in this space. Axil’s bridging role between Japan and global markets helps accelerate innovation diffusion and capital flow, influencing the broader ecosystem by enabling startups to scale and commercialize breakthrough technologies[1][2][5].
Looking ahead, Axil Capital is poised to deepen its impact by continuing to back transformative biomedical innovations and expanding its global reach. Trends such as AI in drug discovery, personalized medicine, and digital therapeutics will likely shape its investment focus. As healthcare challenges grow more complex, Axil’s role as a strategic partner to startups will become increasingly vital, potentially positioning it as a key player in shaping the future of global life sciences innovation.
This outlook ties back to Axil Capital’s founding vision of fostering synergies between Japan and the world, supporting technologies that not only promise financial returns but also meaningful societal benefits[1][2][4].
Key people at Axil Capital.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 1, 2022 | LUCA Science | $29.0M Series B | — | 4BIO Capital, Astellas Venture Management, Mogrify, Parkwalk Advisors, Remiges Ventures, Sana Capital, Jonathan Milner |
| Jun 1, 2022 | DEM BioPharma | $70.0M Series A | — | 4BIO Capital, Adjuvant Capital, Agent Capital, Alta Partners, Astellas Venture Management, Cofounders Capital, Domain Associates, Insight Partners, Leaps by Bayer, Longwood Fund, Novartis Venture Fund, Remiges Ventures |
| Mar 1, 2021 | TechsoMed | $7.0M Series B | — | 4BIO Capital, Astellas Venture Management, Remiges Ventures |
| Aug 1, 2020 | LUCA Science | $10.0M Series A | — | 4BIO Capital, Astellas Venture Management, Mogrify, Parkwalk Advisors, Remiges Ventures, Sana Capital, Jonathan Milner |
| May 1, 2019 | TechsoMed | $3.0M Venture Round | — | 4BIO Capital, Astellas Venture Management, Remiges Ventures |
| Jan 1, 2019 | Frequency Therapeutics | $42.0M Series B | — | — |
